Drug maker Novartis announced that it will seek a fourth indication—nonradiographic axial spondyloarthritis (nr-axSpA)—for its secukinumab (Cosentyx) in the United States after its phase 3 PREVENT trial met its 52-week primary end point.
Drug maker Novartis announced that it will seek a fourth indication—nonradiographic axial spondyloarthritis (nr-axSpA)—for its secukinumab (Cosentyx) in the United States after its phase 3 PREVENT trial met its 52-week primary end point.
The interleukin-17 (IL-17) inhibitor is already approved to treat ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
The ongoing PREVENT trial, a 2-year, randomized, double-blind, placebo-controlled study, enrolled 555 patients with nr-axSpA, and the primary end point was Assessment in SpondyloArthritis International Society criteria for 40% improvement (ASAS40) at weeks 16 and 52.
Patients in this study had been taking at least 2 different nonsteroidal anti-inflammatory agents previously, and some patients had received an anti—tumor necrosis factor (anti-TNF) drug in the past. Patients were randomized to receive 150 mg of secukinumab subcutaneously once per month after 4 weekly induction doses, 150 mg of secukinumab subcutaneously once per month without a loading dose, or placebo. In addition to meeting its primary end point, the trial showed a clinically meaningful reduction in disease activity versus placebo, said the drug maker.
“Non-radiographic axial spondyloarthritis is a chronic debilitating disease, which left untreated can have a significant impact on patients’ quality of life,” said Atul Deodhar, MD, professor of medicine and medical director of Rheumatology Clinics at Oregon Health and Science University, and an investigator in the trial, in a statement. “These positive results indicate a potential new treatment option to help patients experience relief from the signs and symptoms of their disease.”
Novartis has already sought an indication in nr-axSpA in the European Union after having submitted 16-week data to the European Medicines Agency for consideration. Those data, which the drug maker said will be presented at a future scientific congress, show that the trial met its primary end point ASAS40 at week 16.
If secukinumab succeeds in gaining an indication for nr-axSpA, it could compete for an increased share of the inflammatory disease market against an increasing number of US and EU biosimilars, including the recent influx of biosimilar anti-TNF options in the European Union.
It could also see a boost from recent changes to treatment guidelines; in the most recent update to the American College of Rheumatology, the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network’s guideline for axial spondyloarthritis, although anti-TNF options are recommended over secukinumab, the guideline recommends treatment with an IL-17 inhibitor among patients who have primary nonresponse to a first anti-TNF agent rather than cycling to other anti-TNFs.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.